ACADIA Pharmaceuticals $ACAD started a Phase 3 study, dubbed as ENHANCE-1, evaluating NUPLAZID (pimavanserin) for adjunctive treatment of schizophrenia in patients who have failed to respond to antipsychotic therapy, a symptom that affects roughly 30% of schizophrenia victims.